Applied Therapeutics, Inc. (APLT)

NASDAQ: APLT · IEX Real-Time Price · USD
0.845
-0.025 (-2.83%)
At close: Dec 9, 2022 4:00 PM
0.880
+0.035 (4.09%)
After-hours: Dec 9, 2022 4:29 PM EST
-2.83%
Market Cap 41.81M
Revenue (ttm) n/a
Net Income (ttm) -95.24M
Shares Out 48.00M
EPS (ttm) -4.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 64,279
Open 0.85
Previous Close 0.87
Day's Range 0.8 - 0.864
52-Week Range 0.5 - 10.34
Beta 1.65
Analysts Buy
Price Target 11.73 (+1,287.5%)
Earnings Date Nov 11, 2022

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III c... [Read more]

Industry Biotechnology
IPO Date May 14, 2019
Employees 26
Stock Exchange NASDAQ
Ticker Symbol APLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for APLT stock is "Buy." The 12-month stock price forecast is 11.73, which is an increase of 1,287.51% from the latest price.

Price Target
$11.73
(1,287.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions Nove...

NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

1 month ago - GlobeNewsWire

Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Car...

NEW YORK, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

1 month ago - GlobeNewsWire

Applied Therapeutics Announces Positive Data Trend in AT-007 ACTION-Galactosemia Kids Pediatric Trial; Trial Will Con...

• The study did not yet reach statistical significance at 12 months of treatment; however, AT-007 (gavorostat) demonstrated a trend in clinical benefit vs. placebo • Applied Therapeutics plans to meet w...

2 months ago - GlobeNewsWire

Bears are Losing Control Over Applied Therapeutics Inc. (APLT), Here's Why It's a 'Buy' Now

After losing some value lately, a hammer chart pattern has been formed for Applied Therapeutics Inc. (APLT), indicating that the stock has found support. This, combined with an upward trend in earnings ...

3 months ago - Zacks Investment Research

Applied Therapeutics Reports Second Quarter 2022 Financial Results

Completed public equity offering with gross proceeds of $30 million

3 months ago - GlobeNewsWire

Applied Therapeutics, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

5 months ago - GlobeNewsWire

Applied Therapeutics, Inc. Announces Public Offering of Common Stock and Warrants

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against v...

5 months ago - GlobeNewsWire

Applied Therapeutics Receives Orphan Medicinal Product Designation from the EMA for AT-007 for Treatment of Galactosemia

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

6 months ago - GlobeNewsWire

Applied Therapeutics to Present at the UBS Global Healthcare Conference

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecula...

6 months ago - GlobeNewsWire

Applied Therapeutics Reports First Quarter 2022 Financial Results

Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 Continued progress in three Phase 3 trials in areas of high unmet medic...

6 months ago - GlobeNewsWire

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

Other symbols: ANGNBOLTIKNALABP
6 months ago - Zacks Investment Research

Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecu...

8 months ago - GlobeNewsWire

Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Gen...

NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecu...

8 months ago - GlobeNewsWire

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 Progress in Three Phase 3 Trials in Areas of High Unmet Clinical ...

8 months ago - GlobeNewsWire

Applied Therapeutics Supports 15th Annual Rare Disease Day

NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

9 months ago - GlobeNewsWire

Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

9 months ago - GlobeNewsWire

APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Appl...

NEW YORK--(BUSINESS WIRE)-- #Applied--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied The...

10 months ago - Business Wire

APLT INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Applied Therapeutics, Inc. (APLT) Investors t...

SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ -- Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible...

10 months ago - PRNewsWire

SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)---- $APLT #classactioninvestigation--Applied Therapeutics, Inc. (APLT) Holds Submission of New Drug Application for AT-007

10 months ago - Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the...

11 months ago - Business Wire

Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations

Boston, Massachusetts--(Newsfile Corp. - January 4, 2022) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Applied Therapeutics, Inc...

11 months ago - Newsfile Corp

Why Applied Therapeutics Stock Is Sliding Today

The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.

11 months ago - The Motley Fool

Why Applied Therapeutics Shares Are Falling Today

Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia. The ...

11 months ago - Benzinga

Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder

Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency...

11 months ago - Benzinga

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecul...

11 months ago - GlobeNewsWire